Navigation Links
Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Actos Litigation
Date:7/25/2013

New York, New York (PRWEB) July 25, 2013

Actos bladder cancer lawsuit claims continue to move forward in the federal multidistrict litigation now underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to an Order issued by the Court on July 24th, U.S. District Judge Rebecca Doherty has granted the Takeda Defendants’ Unopposed Motion requesting additional time to seek clarification or to appeal the Court’s recent ruling on various discovery issues. The original ruling was issued on July 10th by Magistrate Judge Hanna, who is scheduled to discuss the matter with the parties on July 25th. The Order issued by Judge Doherty grants the parties until July 31st to seek clarification or appeal the ruling. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We continue to receive Actos lawsuit inquiries from individuals who took this drug for long periods of time, and were later diagnosed with bladder cancer. We are pleased to see the Actos bladder cancer litigation moving forward,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease following long-term use of the drug.

Actos Lawsuits
Actos was approved by the U.S. Food & Drug Administration in 1998 to treat Type 2 diabetes. Pioglitazone, the active ingredient in Actos, is also sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact). In June 2011, the FDA warned that long-term use of Actos (one year or more) had been associated with an increased risk of bladder cancer.* According to Bloomberg.com, Actos was also pulled from the market in Germany and France that month because of its link to the disease.** Last month, India’s drug regulator announced a ban on Actos and other pioglitazone-containing drugs, citing an association with bladder cancer and congestive heart failure.***

According to court documents, more than 2,400 Actos bladder cancer lawsuits are pending in the federal multidistrict litigation underway in Louisiana, where the first trial is scheduled to begin on January 27, 2014. All of the complaints allege Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer.

In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Victims of bladder cancer potentially associated with long-term Actos use may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

*fda.gov/drugs/drugsafety/ucm259150.htm, FDA, June 15, 2011
**bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html, Bloomberg, March 5, 2013
indiatoday.intoday.in/story/govt-bans-drugs-anti-diabetes-analgin-pioglitazone-anti-depressant-deanxit-drugs-and-cosmetic-act/1/285575.html, India Today, June 27, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10965597.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion ... and safety labels , has been featured in the National Electrical Manufacturers ... eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication ...
(Date:5/24/2016)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. Drs. ... a complete dental treatment plan that is unique to each smile. , Dr. Kayne ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... ... May 24, 2016 , ... Today ... module. The cutting-edge feature provides end users with an embedded, real time ... intelligence solution and its analytics engine. , This powerful addition to ...
(Date:5/24/2016)... TN (PRWEB) , ... May 24, 2016 , ... ... vitamin alkaline water, a revolutionary new beverage for pregnant women to prevent morning ... prenatal vitamins and alkaline minerals with the look and taste of water. , ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... COUNTY, Calif. , May 19, 2016 /PRNewswire/ ... two thirds of the world lacks basic diagnostic ... procedures in the United States ... privileged to such technology. In fact, the WHO ... at risk of avoidable or treatable death, simply ...
(Date:5/19/2016)... -- According to a new market research report "Sunitinib ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected ... 13.9% from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... spread through 26 Pages and in-depth TOC on "Sunitinib ...
(Date:5/19/2016)... , The data will be presented in ... The conclusions of the study point to a ... 90% of the m presenting duration ... of the patients had clinical benefit.     ... study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed ...
Breaking Medicine Technology: